 In 2016, the FDA eliminated the day 3 and day 14 visits and increased the maximum gestational age from 7 to 10 weeks. They also eliminated the requirements that prescribers be doctors and report serious non-fatal adverse events to the agency. The piecemeal analysis they engaged in relied on studies that included safety measures like ultrasounds that were admitted under the labeled conditions of use and didn't rely on any study that addressed the comprehensive changes.